Cellular Biomedicine Group (CBMG) Acquiring Chinese PLA General Hospital's CAR-T (CD19/CD20/CD30/EGFR) Immuno-Oncology Techno...
February 09 2015 - 8:00AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine company engaged in the development of
cellular therapies for degenerative and cancerous diseases, today
announced its acquisition of Chinese PLA General Hospital's
("PLAGH", Beijing, also known as "301 Hospital") Chimeric Antigen
Receptor T cell (CAR-T) therapy, its recombinant expression vector
CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR
or HER1) Immuno-Oncology patents (all pending), and Phase I/II
clinical data of the aforementioned therapies and manufacturing
knowledge.
"This CAR-T cell technology acquisition further accelerates
CBMG's growth in the Immuno-Oncology segment. We look forward to
working with PLAGH as a long-term partner as we evaluate paths to
commercialization," commented Dr. William (Wei) Cao, Chief
Executive Officer of Cellular Biomedicine Group.
CAR-T cell therapy involves engineering cancer patients' own
immune cells to recognize and attack their tumors. Wei Dong Han,
MD, PhD, head of PLAGH's Biotherapy Department, is a renowned key
opinion leader in the cancer immunotherapy field. Professor Han's
team has conducted several preliminary clinical studies of various
CAR-T constructs targeting CD19-positive acute lymphoblastic
leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma
and EGFR-HER1-positive advanced lung cancer. PLAGH is a top-ranking
medical center in China, holding to the highest academic standards.
The hospital consists of 125 clinical, medical and technological
departments and 4,000 patient beds, with annual volumes of
approximately 4 million patients and more than 65,000
surgeries.
Prior to acquiring PLAGH's technology, the Company has made
progress with recent acquisitions of Agreen Biotech Co. Ltd. and
its T-Cell Memory technology (Tcm), T Cell Receptor clonality
analysis technology, as well as another third generation CAR-T,
anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from
Persongen Biotechnology Ltd. Together with PLAGH's technology,
CBMG's state-of-the art infrastructure and clinical platform, along
with these acquired technologies will enable improvement of cancer
immune cell therapies and strategic combination therapies which
will boost the Company's Immuno-Oncology presence, and pave the way
for future partnerships.
"We are very impressed by the quality of the work done by Dr.
Han and his team at PLAGH, and are excited by the safe and
efficacious profile of these novel T cell therapies for cancerous
diseases, which we deem necessary to be a leader in this field
while providing alluring prospective therapies for other cancers.
This is the beginning of a long-term strategic partnership between
CBMG and PLAGH. Together, we will expeditiously continue our quest
in developing safer and more effective cancer immunotherapy
programs with leading hospitals and other partners," said Dr.
William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine
Group.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024